Repligen Corporation
NASDAQ:RGENMedical - Instruments & Supplies
-$3.66 today
- Market cap
- $11.04B
- Beta
- 1.08
- P/E (TTM)
- 142.4
- EPS (TTM)
- $0.91
Volume 1.30M
Average 1.08M
RGEN Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Repligen CorporationNASDAQ: RGEN
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents falls 14.4% from a year ago
Cash & equivalents stood at $606.78M at the end of Q2 FY2026, down 14.4% from a year earlier and up 4.1% from the prior quarter. Over 3 fiscal years it compounded at +2.6% a year.
Context
- Cash & equivalents amounted to 20.6% of total assets at the end of Q2 FY2026, down 3.9 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -14.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 566.02M USD
- Year-over-year change
- -25.3%
- 4-year CAGR
- -1.6%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 566.02M | -25.3% |
| FY2024 | 2024-12-31 | 757.36M | +0.8% |
| FY2023 | 2023-12-31 | 751.32M | +43.5% |
| FY2022 | 2022-12-31 | 523.46M | -13.3% |
| FY2021 | 2021-12-31 | 603.81M | — |
Cash & Equivalents vs competitors
How RGEN compares with its peers on the latest reported figures
- RGEN's Jun 2026 cash & equivalents of $606.78M is the 4th highest of the 9 companies compared; the peer median is $433.52M.
- Its year-over-year change of -14.4% is the 6th highest of 9, against a peer median of +9.6%.
- Cash & equivalents amounts to 20.6% of total assets for RGEN, versus a peer median of 8.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $5.46B | +175.5% | +4.9% | 4.8% | |
| Jul 2026 | $1.76B | +14.5% | +19.3% | 12.6% | |
| Jun 2026 | $768.5M | +4.7% | +4.7% | 13.0% | |
| Jun 2026 | $606.78M | -14.4% | +2.6% | 20.6% | |
| Jun 2026 | $517M | +40.0% | +7.0% | 5.0% | |
| Sep 2026 | $350.04M | +141.5% | +13.6% | 13.3% | |
| Jun 2026 | $306.8M | -31.7% | -0.7% | 2.6% | |
| Jun 2026 | $70.09M | -74.0% | -30.0% | 11.6% | |
| Mar 2026 | $22.82M | -65.9% | +19.3% | 5.7% | |
| Peer median (excluding RGEN) | $433.52M | +9.6% | +6.0% | 8.7% | |
Competitors are the stored peer set for RGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 603.81M | 523.46M | 751.32M | 757.36M | 566.02M |
| Short-term Investments | 0 | 100.3M | 0 | 0 | 201.61M |
| Net Receivables | 117.42M | 116.25M | 124.16M | 134.12M | 158.59M |
| Inventory | 184.49M | 238.28M | 202.32M | 142.96M | 170.46M |
| Other Current Assets | 19.27M | 17.41M | 19.92M | 20.6M | 27.14M |
| Total Current Assets | 931.68M | 998.12M | 1.11B | 1.07B | 1.14B |
| Property, Plant & Equipment (Net) | 226.52M | 315.7M | 322.96M | 333.12M | 306.15M |
| Goodwill | 860.36M | 855.51M | 987.12M | 1.03B | 1.11B |
| Intangible Assets | 337.27M | 360.62M | 406.96M | 397.9M | 386.15M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 1.9M | 840K | 1.53M | 749K | 694K |
| Other Non-current Assets | 615K | 815K | 1.28M | 868K | 4.91M |
| Total Non-current Assets | 1.43B | 1.53B | 1.72B | 1.76B | 1.81B |
| Total Assets | 2.36B | 2.53B | 2.83B | 2.83B | 2.95B |
| Account Payables | 36.2M | 27.55M | 19.56M | 32.13M | 30.01M |
| Short-term Debt | 255.26M | 284.62M | 69.45M | 0 | 21.56M |
| Tax Payables | 4.98M | 2.46M | 6.81M | 0 | 0 |
| Deferred Revenue | 14.68M | 19.28M | 17.07M | 13.24M | 14.61M |
| Other Current Liabilities | 42.15M | 47.47M | 29.64M | 49.29M | 25.92M |
| Total Current Liabilities | 375.26M | 404.2M | 164.94M | 126.79M | 135.83M |
| Long-term Debt | 0 | 0 | 510.14M | 525.57M | 542.21M |
| Deferred Tax Liabilities | 33.48M | 23M | 39.32M | 22.78M | 22.5M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 1.54M |
| Other Non-current Liabilities | 97.05M | 62.32M | 25.35M | 36.24M | 15.32M |
| Total Non-current Liabilities | 233.03M | 216.7M | 701.4M | 730.16M | 707.74M |
| Total Liabilities | 608.29M | 620.9M | 866.34M | 856.95M | 843.57M |
| Common Stock | 553K | 556K | 558K | 561K | 563K |
| Retained Earnings | 194.06M | 397.27M | 432.87M | 407.35M | 456.25M |
| Accumulated OCI | (16.89M) | (34.39M) | (37.81M) | (52.53M) | (2.53M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 1.75B | 1.91B | 1.96B | 1.97B | 2.11B |
| Total Debt | 366.05M | 422.96M | 711.8M | 686.25M | 689.95M |
| Net Debt | (237.76M) | (100.5M) | (39.52M) | (71.11M) | 123.93M |
Repligen Corporation
NASDAQ:RGEN
Intrinsic Alpha fair value
Locked
Current Price
$172.67
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.